(R)-4-(2-oxo-4-propyloxazolidin-3-yl)benzoic acid → (R)-3-{4-[4-(3,5-dimethylpyridin-2-yl)piperazine-1-carbonyl]phenyl}-4-propyloxazolidin-2-one
반응식
[O:1]=[C:2]1[N:6]([C:7]2[CH:15]=[CH:14][C:10]([C:11]([OH:13])=O)=[CH:9][CH:8]=2)[C@H:5]([CH2:16][CH2:17][CH3:18])[CH2:4][O:3]1.Cl.[CH3:20][C:21]1[C:22]([N:28]2[CH2:33][CH2:32][NH:31][CH2:30][CH2:29]2)=[N:23][CH:24]=[C:25]([CH3:27])[CH:26]=1>>[CH3:20][C:21]1[C:22]([N:28]2[CH2:29][CH2:30][N:31]([C:11]([C:10]3[CH:9]=[CH:8][C:7]([N:6]4[C@H:5]([CH2:16][CH2:17][CH3:18])[CH2:4][O:3][C:2]4=[O:1])=[CH:15][CH:14]=3)=[O:13])[CH2:32][CH2:33]2)=[N:23][CH:24]=[C:25]([CH3:27])[CH:26]=1참가 물질
3
실험 절차
By reaction and treatment in the same manner as in Example 49 and using (R)-4-(2-oxo-4-propyloxazolidin-3-yl)benzoic acid (498 mg) described in Preparation Example 79 and 1-(3,5-dimethylpyridin-2-yl)piperazine hydrochloride (455 mg) described in Preparation Example 64, the title compound (239 mg) was obtained.
후처리
- customBy reaction and treatment in the same manner as in Example 49